New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
August 23, 2024 - The FDA approved Amgen’s Pavblu (aflibercept-ayyh), biosimilar to Regeneron’s Eylea® (aflibercept).
Download PDF
Return to publications
